# Oleanolic acid–chitosan compound inhibits mitochondrial autophagy and malignant transformation of lung cancer through the PTEN/AKT pathway

**Authors:** Abulimiti ABULAITI, XiaoHong SUN, Waresijiang YIBULAYIN, Dan HE, KeMing XU, Xiayimaierdan YIBULAYIN

PMC · DOI: 10.55730/1300-0144.6163 · 2025-09-23

## TL;DR

A compound made of oleanolic acid and chitosan fights lung cancer by affecting cell survival and autophagy through a key signaling pathway.

## Contribution

The study reveals that OAC inhibits lung cancer by modulating the PTEN/AKT pathway to induce apoptosis and autophagy.

## Key findings

- OAC significantly reduced cell viability and proliferation in A549 lung cancer cells.
- OAC induced apoptosis and autophagy, marked by changes in key protein expressions and mitochondrial dysfunction.
- PTEN overexpression enhanced the effects of OAC on apoptosis and autophagy.

## Abstract

Oleanolic acid–chitosan compound (OAC) shows potent antinonsmall cell lung cancer (NSCLC) activity, but its mechanisms remain unclear. This study elucidates how OAC modulates autophagy and apoptosis via the Phosphatase and Tensin Homolog/Protein Kinase B (PTEN/AKT) signaling pathway.

Oleanolic acid was coupled with chitosan to synthesize OAC. A549 and MRC-5 cells were cultured in Dulbecco’s Modified Eagle Medium and Minimum Essential Medium, respectively, supplemented with 10% fetal bovine serum and penicillin–streptomycin. Cells were pretreated with chloroquine before OAC treatment. Cell viability was assessed using the CCK-8 assay, while 5-bromo-2′-deoxyuridine (BrdU) and colony formation tests were employed to evaluate cell proliferation. Apoptosis was measured by flow cytometry using Annexin V-FITC/PI (fluorescein isothiocyanate/propidium iodide) staining. Autophagy was monitored through western blot analysis of LC3, SQSTM1, Atg5, Beclin1, and LAMP1, and confirmed by immunofluorescence and transmission electron microscopy (TEM). Mitochondrial membrane potential (MMP) was determined by JC-1 staining, and acridine orange staining was used to detect acidic vesicular organelles (AVOs). Additionally, PTEN overexpression was induced by transfecting cells with the hemagglutinin tag (HA)-PTEN plasmid.

OAC treatment significantly inhibited cell viability and proliferation in A549 cells, as evidenced by decreased CCK-8 absorbance, reduced BrdU incorporation, and fewer colony formations. Flow cytometry revealed a marked increase in apoptotic cells following OAC treatment. Western blot analysis demonstrated altered expression levels of apoptosis-related proteins (Bcl-2, Bax, Cytochrome c, caspase-9, caspase-3, PARP) and autophagy markers (LC3, SQSTM1, Atg5, Beclin1, LAMP1). Immunofluorescence and TEM further confirmed the induction of autophagy. AO staining showed increased AVOs, while JC-1 staining indicated a reduction in MMP. PTEN overexpression enhanced OAC-induced apoptosis and autophagy.

OAC effectively inhibits cell proliferation and induces apoptosis and autophagy in A549 cells, with PTEN playing a regulatory role in these processes. These findings suggest that OAC may serve as a potential therapeutic agent for cancer treatment.

## Linked entities

- **Genes:** PTEN (phosphatase and tensin homolog) [NCBI Gene 5728], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596], BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581], Cyt-c-d (Cytochrome c distal) [NCBI Gene 34995], Casp9 (caspase 9) [NCBI Gene 12371], Casp3 (caspase 3) [NCBI Gene 12367], PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142], MAP1LC3A (microtubule associated protein 1 light chain 3 alpha) [NCBI Gene 84557], SQSTM1 (sequestosome 1) [NCBI Gene 8878], ATG5 (autophagy related 5) [NCBI Gene 9474], BECN1 (beclin 1) [NCBI Gene 8678], LAMP1 (lysosome associated membrane protein 1) [NCBI Gene 3916]
- **Chemicals:** Oleanolic acid (PubChem CID 10494), chitosan (PubChem CID 129662530), chloroquine (PubChem CID 2719), CCK-8 (PubChem CID 9833444), 5-bromo-2′-deoxyuridine (BrdU) (PubChem CID 6035), JC-1 (PubChem CID 5492929), acridine orange (PubChem CID 62344)
- **Diseases:** lung cancer (MONDO:0005138)

## Full-text entities

- **Genes:** BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, BECN1 (beclin 1) [NCBI Gene 8678] {aka ATG6, VPS30, beclin1}, SQSTM1 (sequestosome 1) [NCBI Gene 8878] {aka A170, DMRV, EBIAP, FTDALS3, NADGP, OSIL}, ATG5 (autophagy related 5) [NCBI Gene 9474] {aka APG5, APG5-LIKE, APG5L, ASP, SCAR25, hAPG5}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, COL11A2 (collagen type XI alpha 2 chain) [NCBI Gene 1302] {aka DFNA13, DFNB53, FBCG2, HKE5, OSMEDA, OSMEDB}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, LAMP1 (lysosome associated membrane protein 1) [NCBI Gene 3916] {aka CD107a, LAMPA, LGP120}, MAP1LC3A (microtubule associated protein 1 light chain 3 alpha) [NCBI Gene 84557] {aka ATG8E, LC3, LC3A, MAP1ALC3, MAP1BLC3}
- **Diseases:** lung cancer (MESH:D008175), cancer (MESH:D009369)
- **Chemicals:** propidium iodide (MESH:D011419), Dulbecco's Modified Eagle Medium (-), JC-1 (MESH:C068624), penicillin (MESH:D010406), Oleanolic acid (MESH:D009828), chloroquine (MESH:D002738), acridine (MESH:D000166), PI (MESH:D010716), chitosan (MESH:D048271), 5-bromo-2'-deoxyuridine (MESH:D001973), streptomycin (MESH:D013307), CCK-8 (MESH:D012844)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12974302/full.md

---
Source: https://tomesphere.com/paper/PMC12974302